Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL
Open Access
- 10 October 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 67 (1) , 213-217
Abstract
It is currently debated whether patients with residual viraemia are at higher risk of virological failure than those attaining P = 0.231). CD4+ cell recovery (slope) was significantly less in the patients with residual viraemia; +14.3 (−7.7, 43.9) cells/mm3 per year versus +21.2 (−2.5, 53.2) cells/mm3 per year; P = 0.036. Residual viraemia assessed by kPCR was not associated with virological rebound during 1 year of follow-up. However, the patients attaining <1 HIV RNA copy/mL showed a small but statistically significant improvement in CD4+ cell recovery.Keywords
This publication has 7 references indexed in Scilit:
- Antiretroviral Treatment of Adult HIV InfectionJAMA, 2010
- Evaluation of the new VERSANT HIV-1 RNA 1.0 Assay (kPCR) for quantitative detection of human immunodeficiency virus type 1 RNAJournal of Clinical Virology, 2009
- Comparative evaluation of the VERSANT® HIV-1 RNA 1.0 kinetic PCR molecular system (kPCR) for the quantification of HIV-1 plasma viral loadJournal of Clinical Virology, 2009
- Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapyProceedings of the National Academy of Sciences, 2008
- ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy ViremiaPLOS Pathogens, 2007
- Relative Prognostic Value of Self-Reported Adherence and Plasma Nnrti/Pi Concentrations to Predict Virological Rebound in Patients Initially Responding to HaartAntiviral Therapy, 2004
- Patient-Reported Nonadherence to HAART Is Related to Protease Inhibitor LevelsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000